Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | 103.87%838.6M | ---- | -44.77%411.33M | ---- | -64.39%744.8M | ---- | 129.06%2.09B | ---- | -14.31%913.07M |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | 10.93%-187.03M | ---- | 24.24%-209.98M | ---- | -43.06%-277.16M | ---- | -36.71%-193.74M | ---- | -233.88%-141.72M |
| Impairment and provisions: | ---- | -96.89%274K | ---- | -6.72%8.81M | ---- | 593.10%9.45M | ---- | -83.20%1.36M | ---- | 9,673.49%8.11M |
| -Impairment of trade receivables (reversal) | ---- | -96.89%274K | ---- | -6.72%8.81M | ---- | 593.10%9.45M | ---- | -83.20%1.36M | ---- | 9,673.49%8.11M |
| Revaluation surplus: | ---- | -44.97%-4.22M | ---- | -16.25%-2.91M | ---- | 78.48%-2.5M | ---- | ---11.64M | ---- | ---- |
| -Other fair value changes | ---- | -44.97%-4.22M | ---- | -16.25%-2.91M | ---- | 78.48%-2.5M | ---- | ---11.64M | ---- | ---- |
| Asset sale loss (gain): | ---- | -164.60%-250K | ---- | 114.48%387K | ---- | -303.12%-2.67M | ---- | 3,274.36%1.32M | ---- | 112.50%39K |
| -Loss (gain) on sale of property, machinery and equipment | ---- | -164.60%-250K | ---- | 114.48%387K | ---- | -303.12%-2.67M | ---- | 3,274.36%1.32M | ---- | 112.50%39K |
| Depreciation and amortization: | ---- | 7.50%839.47M | ---- | 8.78%780.94M | ---- | 12.73%717.89M | ---- | 26.00%636.82M | ---- | 23.73%505.42M |
| -Depreciation | ---- | 7.53%838.1M | ---- | 8.87%779.39M | ---- | 12.82%715.92M | ---- | 26.09%634.55M | ---- | 23.85%503.25M |
| -Amortization of intangible assets | ---- | -11.53%1.37M | ---- | -21.38%1.54M | ---- | -13.59%1.96M | ---- | 4.65%2.27M | ---- | 0.09%2.17M |
| Financial expense | ---- | 10.24%132.49M | ---- | -44.44%120.18M | ---- | -19.57%216.31M | ---- | 37.09%268.93M | ---- | -8.67%196.18M |
| Exchange Loss (gain) | ---- | -37.36%29.04M | ---- | 198.83%46.37M | ---- | -205.33%-46.91M | ---- | --44.54M | ---- | ---- |
| Special items | ---- | ---- | ---- | ---91K | ---- | ---- | ---- | ---- | ---- | 91.78%-3.73M |
| Operating profit before the change of operating capital | ---- | 42.71%1.65B | ---- | -15.02%1.16B | ---- | -52.13%1.36B | ---- | 92.17%2.84B | ---- | -8.31%1.48B |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | -84.42%-845.26M | ---- | 60.67%-458.34M | ---- | -27.51%-1.17B | ---- | -441.37%-914.02M | ---- | 141.92%267.75M |
| Accounts receivable (increase)decrease | ---- | -196.64%-939.05M | ---- | 53.93%-316.56M | ---- | -66.49%-687.18M | ---- | -165.18%-412.74M | ---- | 44.59%-155.65M |
| Accounts payable increase (decrease) | ---- | 280.83%1.12B | ---- | -117.10%-621.91M | ---- | -27.02%3.64B | ---- | 4,621.63%4.98B | ---- | -102.95%-110.22M |
| Special items for working capital changes | ---- | -121.42%-40.79M | ---- | 445.73%190.39M | ---- | ---55.07M | ---- | ---- | ---- | -53.58%214K |
| Cash from business operations | -301.62%-2.84B | 1,944.87%947.89M | 213.42%1.41B | -101.66%-51.38M | -178.86%-1.24B | -52.45%3.09B | -51.06%1.58B | 339.07%6.5B | 882.38%3.22B | -66.56%1.48B |
| Other taxs | -612.21%-83.64M | 36.60%-26.74M | -431.88%-11.74M | 76.55%-42.17M | 98.05%-2.21M | 41.65%-179.84M | 12.71%-113.21M | -130.85%-308.2M | -60.04%-129.71M | 14.45%-133.51M |
| Net cash from operations | -309.29%-2.93B | 1,084.63%921.15M | 212.28%1.4B | -103.22%-93.55M | -185.11%-1.24B | -52.99%2.91B | -52.67%1.46B | 359.73%6.19B | 727.33%3.09B | -68.47%1.35B |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | ---- | -28.43%129.48M | ---- | 16.65%180.92M | ---- | 13.84%155.09M | ---- | 61.77%136.23M | ---- | --84.21M |
| Decrease in deposits (increase) | 268.96%1.08B | -162.13%-702.44M | -173.00%-637.56M | 1,017.52%1.13B | 160.93%873.37M | 95.00%-123.22M | -142.65%-1.43B | -82.53%-2.47B | 45.88%-590.72M | 41.96%-1.35B |
| Sale of fixed assets | ---- | --1.69M | --361K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Purchase of fixed assets | 81.77%-9.94M | 88.29%-19.23M | 7.62%-54.55M | -230.55%-164.21M | -3,437.93%-59.05M | 74.69%-49.68M | 99.16%-1.67M | -3,925,600.00%-196.29M | 52.47%-199.79M | 96.48%-5K |
| Purchase of intangible assets | ---- | ---- | ---- | ---- | ---- | -9.08%-1.67M | ---- | ---1.53M | ---- | ---- |
| Recovery of cash from investments | ---- | ---- | ---- | -97.99%50M | -83.36%50M | --2.48B | --300.48M | ---- | ---- | -81.71%312.82M |
| Cash on investment | -190.39%-243.5M | 77.53%-194.68M | 88.48%-83.85M | 81.16%-866.22M | 32.40%-728M | -186.86%-4.6B | -41.22%-1.08B | 5.67%-1.6B | ---762.54M | -1.85%-1.7B |
| Other items in the investment business | -26.59%125.59M | ---- | 33.38%171.08M | ---- | 195.18%128.26M | ---- | 14.67%43.45M | -83.61%139K | -6.20%37.89M | 101.19%848K |
| Net cash from investment operations | 257.04%949.34M | -337.19%-785.18M | -328.48%-604.52M | 115.52%331.03M | 112.20%264.58M | 48.35%-2.13B | -43.09%-2.17B | -55.72%-4.13B | -30.19%-1.52B | -12.53%-2.65B |
| Net cash before financing | -349.11%-1.98B | -42.74%135.98M | 180.91%793.26M | -69.40%237.48M | -38.98%-980.37M | -62.29%776.1M | -144.78%-705.38M | 257.61%2.06B | 195.10%1.58B | -168.31%-1.31B |
| Cash flow from financing activities | ||||||||||
| New borrowing | 299.89%4.89B | -50.98%2.05B | -54.25%1.22B | 101.87%4.19B | 79.05%2.67B | -31.75%2.07B | -18.96%1.49B | -44.74%3.04B | -38.92%1.84B | 30.67%5.5B |
| Refund | -25.61%-1.94B | 54.71%-1.97B | 7.64%-1.54B | -72.39%-4.35B | -213.39%-1.67B | 49.54%-2.52B | 83.37%-532.27M | -31.84%-5B | -196.52%-3.2B | 37.06%-3.79B |
| Interest paid - financing | -9.09%-96K | 6.19%-138.31M | 18.52%-88K | 39.03%-147.44M | 14.29%-108K | 16.35%-241.81M | 12.50%-126K | -15.38%-289.06M | 13.77%-144K | -15.78%-250.52M |
| Issuance expenses and redemption of securities expenses | 47.93%-1.4M | -843.98%-11.38M | -1,748.97%-2.68M | ---1.21M | ---145K | ---- | ---- | 57.06%-2.97M | ---- | 74.63%-6.91M |
| Other items of the financing business | 31.47%-57.98M | ---- | -11.61%-84.6M | ---- | 42.63%-75.8M | ---- | 12.22%-132.13M | ---- | -74.64%-150.52M | ---- |
| Net cash from financing operations | 813.56%2.89B | 78.45%-66.95M | -143.72%-405.68M | 55.05%-310.73M | 12.13%927.8M | 69.32%-691.23M | 154.82%827.47M | -255.42%-2.25B | -181.59%-1.51B | 166.99%1.45B |
| Effect of rate | 141.76%2.05M | 258.77%362K | -112.58%-4.91M | 91.18%-228K | 95.46%39.05M | -284.71%-2.59M | 1,822.33%19.98M | 159.80%1.4M | 46.37%-1.16M | -26.81%-2.34M |
| Net Cash | 137.01%918.62M | 194.23%69.03M | 837.36%387.58M | -186.32%-73.25M | -143.05%-52.56M | 143.53%84.87M | 85.37%122.09M | -235.53%-194.98M | -65.97%65.87M | 157.00%143.86M |
| Begining period cash | 43.88%227.53M | -31.73%158.14M | -31.73%158.14M | 55.10%231.62M | 55.10%231.62M | -56.45%149.34M | -56.45%149.34M | 70.27%342.92M | 70.27%342.92M | -55.80%201.4M |
| Cash at the end | 112.31%1.15B | 43.88%227.53M | 147.96%540.81M | -31.73%158.14M | -25.15%218.11M | 55.10%231.62M | -28.51%291.41M | -56.45%149.34M | 3.77%407.62M | 70.27%342.92M |
| Cash balance analysis | ||||||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | Furimazer Certified Public Accountants Limited | -- | Furimazer Certified Public Accountants Limited | -- | Furimazer Certified Public Accountants Limited | -- | Furimazer Certified Public Accountants Limited | -- | Furimazer Certified Public Accountants Limited |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.